Prolonged Prothrombin Time: A Reliable Clinical Indicator of Therapeutic Efficacy for Chronic Liver Failure Treated...

To analyze the therapeutic efficacy of artificial liver support system (ALSS) treatment for acute on chronic liver failure (ACLF) and its influencing factors, providing a basis for clinical treatment, selection of beneficiaries, and disease management.

A retrospective study was conducted on 283 patients with ACLF who received ALSS treatment at a hospital in Ganzhou City from August 2021 to January 2024. Patients were divided into effective and ineffective subgroups based on the therapeutic efficacy within 28 days. Differences between the two subgroups were compared. Variables with significant differences in univariate analysis were further analyzed using multivariate logistic regression to determine the influencing factors, and ROC curves were constructed to evaluate the predictive efficacy of treatment outcomes.

The efficacy rate of ALSS treatment for ACLF was 59.72%. Univariate analysis showed that levels of Model for End-Stage Liver Disease (MELD) score, prothrombin time (PT), Monocyte-to-Lymphocyte Ratio (MLR), International Normalized Ratio (INR), Creatinine, and Total Cholesterol (TC) were higher in the ineffective group, while Triglycerides (TG), High-Density Lipoprotein Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (HDL-C) were lower. Multivariate logistic regression analysis indicated that PT, MELD score and MLR were key factors influencing the efficacy of ALSS treatment for ACLF patients. ROC curves demonstrated that PT had good performance in assessing therapeutic efficacy (P < .05). The evaluation effect of the combined factors was not significantly different compared with the single effect of PT (P > .05).

The efficacy of ALSS treatment for ACLF was comparatively favorable. Prolonged PT is correlated with treatment efficacy and have significant reference value in the assessment of treatment outcomes.